Xenetic Biosciences (XBIO) Gets a Buy Rating from H.C. Wainwright

By Ryan Adsit

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Xenetic Biosciences (XBIOResearch Report) today and set a price target of $2.00. The company’s shares closed last Thursday at $1.23.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 26.5% and a 54.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Currently, the analyst consensus on Xenetic Biosciences is a Moderate Buy with an average price target of $2.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.10 and a one-year low of $0.44. Currently, Xenetic Biosciences has an average volume of 616.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xenetic Biosciences, Inc. is a biopharmaceutical company, which focuses on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. The XCART has the potential to fuel a robust pipeline of therapeutic assets targeting oncology indications. Additionally, Xenetic is leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. The PolyXen has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. Xenetic Biosciences was founded on and is headquartered in Framingham, MA.